Stay updated on Regeneron Press Releases

Sign up to get notified when there's something new on the Regeneron Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Regeneron Press Releases page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    The page now includes the approval of Dupixent® as the first biologic medicine for COPD in Japan, while the previous announcement regarding EYLEA HD®'s positive Phase 3 results has been removed.
    Difference
    17%
    Check dated 2025-04-01T23:04:17.000Z thumbnail image
  4. Check
    25 days ago
    No Change Detected
  5. Check
    32 days ago
    Change Detected
    Summary
    The page has been updated to include information about the Regeneron Science Talent Search 2025 Awards, which offers over $1.8 million to high school seniors for innovative scientific research. The previous financial report regarding Regeneron's fourth quarter and full year 2024 results has been removed.
    Difference
    23%
    Check dated 2025-03-18T08:52:05.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The page has added information about a late-breaking presentation of pivotal data for Dupixent® in relation to Bullous Pemphigoid, while it has removed details about a competition for high school scientists with significant awards.
    Difference
    14%
    Check dated 2025-03-11T04:25:52.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    The web page has added pagination controls, allowing users to navigate between multiple pages of content more easily.
    Difference
    3%
    Check dated 2025-02-24T20:45:45.000Z thumbnail image
  8. Check
    61 days ago
    Change Detected
    Summary
    The webpage has added significant announcements regarding Regeneron's investor conference presentations and the acceptance of Linvoseltamab's BLA for FDA review, which are crucial updates in the context of pharmaceutical developments.
    Difference
    11%
    Check dated 2025-02-17T14:56:41.000Z thumbnail image
  9. Check
    68 days ago
    Change Detected
    Summary
    The webpage has added significant updates regarding EYLEA HD® (aflibercept) Injection, including positive Phase 3 results and three-year outcomes for patients, while numerous sections related to stock information and corporate governance have been removed.
    Difference
    61%
    Check dated 2025-02-10T09:46:55.000Z thumbnail image

Stay in the know with updates to Regeneron Press Releases

Enter your email address, and we'll notify you when there's something new on the Regeneron Press Releases page.